First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors
收藏NIAID Data Ecosystem2026-03-12 收录
官方服务：
资源简介：
This study is a Phase 1/2, first-in-human, open-label, dose-escalation, and expansion study designed to characterize the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of IMGC936 administered by intravenous (IV) infusion.
创建时间：
2020-10-15
